Kingsley Biotechnology: Expected to significantly increase pre-tax profit year-on-year in the first half of the year.

On the morning of July 22, Kinser Bio-technology announced on the Hong Kong Stock Exchange that for the six months ending on June 30, 2025, the Group is expected to significantly increase its pre-tax profit compared to the previous period, excluding the profit and loss of Legendary Bio-technology shares held by the Group during the reporting period; and the loss of discontinued operations in the previous period due to the demerger of Legendary from the Group on October 18, 2024. Adjusted, the Group is expected to record pre-tax profits of approximately $175.4 million to $204.6 million for the reporting period, while the Group's pre-tax loss in the previous period was approximately $127.9 million.